Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: A population-based cohort study of all patients in western Sweden with long-term follow-up
| Autor: | Margaretha Åkeson, Kalle Dahllöf, György Horvath, Britt-Marie Zetterqvist, Mats Brännström |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Paclitaxel endocrine system diseases medicine.medical_treatment Population Disease-Free Survival Carboplatin Cohort Studies chemistry.chemical_compound Age Distribution Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine education Survival rate Aged Neoplasm Staging Aged 80 and over Ovarian Neoplasms Sweden Gynecology education.field_of_study Chemotherapy Relative survival business.industry Carcinoma Obstetrics and Gynecology General Medicine Middle Aged Prognosis medicine.disease Survival Rate chemistry Chemotherapy Adjuvant Cohort Female business Ovarian cancer Follow-Up Studies Cohort study |
| Zdroj: | Acta Obstetricia et Gynecologica Scandinavica. 87:1343-1352 |
| ISSN: | 1600-0412 0001-6349 |
| DOI: | 10.1080/00016340802495491 |
| Popis: | To evaluate long-term survival and prognostic factors for all epithelial ovarian cancer (EOC) patients after adjuvant treatment with paclitaxel and carboplatin.Prospectively collected data from a population-based cohort.Western Sweden Health Care Region.All women diagnosed with EOC between 1998 and 2005.Data related to age, stage, surgery, histopathology, grade, ploidy status, CA-125, follow-up, recurrence and death of EOC patients (n=976) were prospectively collected in a quality register. No patient was lost to follow-up and the median follow-up was 68 months (range: 27-110).Relative survival at 5 and 8 years for all and for those treated with chemotherapy; median progression-free survival (PFS) for stage IIB-IV patients treated with paclitaxel and carboplatin.Relative 5- and 8-year survival rates in the subgroup of patients treated with chemotherapy after surgery (n=853) were 50.4% (95% CI: 46.4-54.3) and 40.5% (95% CI: 35.4-45.6), respectively. The median relative survival time of the entire group of patients was 60 months (95% CI: 52-73). The median PFS for the patients in stage IIB-IV treated with paclitaxel and carboplatin was 18 months (95% CI: 17-20). Well-established prognostic factors of age, stage, residual tumor and post-operative CA-125 were of prognostic significance.Post-surgical adjuvant chemotherapy of paclitaxel and carboplatin for advanced stages of EOC does not seem to increase the relative 5-year survival rate or the median PFS compared to results of earlier studies of a similar patient cohort from the same geographical area. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|